Skip to main content
Mabpharm Limited logo

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 ISIN · KYG5780F1046 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2021-04-21 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
2020 Annual Report
Regulatory Filings
2021-04-21 English
(1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) N
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Mabpharm Limited dated April 13, 2021, concerning a discloseable and connected transaction related to the acquisition of CMAB807, continuing connected transactions, and a notice of an Extraordinary General Meeting (EGM) scheduled for April 30, 2021. It includes detailed information such as letters from the Board, Independent Board Committee, Independent Financial Adviser, valuation report, and the notice of the EGM itself. The document is comprehensive and intended to inform shareholders about the transaction and the meeting where resolutions will be voted on. This type of document is a circular sent to shareholders to provide information and solicit votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement (PSI). It is not an announcement of voting results (DVA), nor a simple meeting notice (RPA), nor a management or financial report. Therefore, the correct classification is PSI with high confidence.
2021-04-12 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, APRIL 30, 2021
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for an Extraordinary General Meeting (EGM) of Mabpharm Limited. It contains instructions for shareholders to appoint proxies and vote on specific resolutions related to license agreements and contracts. There are no financial statements, management discussions, or detailed financial data. The document is clearly related to shareholder voting procedures for a specific meeting, not a report or announcement of financial results or corporate changes. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (8287 characters) supports it being a full proxy form rather than a brief announcement.
2021-04-12 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice of an Extraordinary General Meeting (EGM) for Mabpharm Limited, detailing the date, time, location, and agenda items for shareholder approval. It includes resolutions to approve agreements and authorizations related to the company's business activities. The document is an announcement of a meeting and the proposed resolutions to be voted on, not a report of the meeting results or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a voting result announcement. The content fits the category of a meeting notice, which is best classified under AGM Information (AGM-R), as it is similar in nature to AGM notices and materials shared for shareholder meetings, even though it is an Extraordinary General Meeting rather than an Annual General Meeting. Given the specificity and detailed agenda, AGM Information is the most appropriate classification.
2021-04-12 English
FURTHER DELAY IN DESPATCH OF CIRCULAR
Report Publication Announcement Classification · 95% confidence The document is an announcement from Mabpharm Limited regarding a further delay in the despatch of a circular related to certain agreements and transactions. It references previous announcements and states that the circular, which contains detailed information and recommendations, will be postponed. The document is short (2508 characters) and primarily serves to inform about the delay and expected new date for the circular's despatch. It does not contain the circular itself or detailed financial data. Therefore, it is an announcement about the timing of a report (the circular) rather than the report itself. According to the 'Menu vs Meal' rule, such announcements are classified as Report Publication Announcements (RPA).
2021-04-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related activities for the month ended 31/03/2021. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating it is a regulatory filing related to share capital movements. The content focuses on share capital changes, share options, and confirmations related to securities issuance, without financial statements or earnings data. This type of document is a regulatory announcement about share capital changes rather than a full financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data on share capital movements, supporting this classification with high confidence.
2021-04-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.